Trial
NCT06320080
Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma.
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Collaborators
—
Condition
Advanced Hepatocellular Carcinoma
Intervention
TQB2223 injection
Why stopped
This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-21